1. Home
  2. IMCR vs DEI Comparison

IMCR vs DEI Comparison

Compare IMCR & DEI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Immunocore Holdings plc

IMCR

Immunocore Holdings plc

HOLD

Current Price

$36.13

Market Cap

1.8B

Sector

Health Care

ML Signal

HOLD

Logo Douglas Emmett Inc.

DEI

Douglas Emmett Inc.

HOLD

Current Price

$11.20

Market Cap

1.9B

Sector

Real Estate

ML Signal

HOLD

Company Overview

Basic Information
Metric
IMCR
DEI
Founded
2008
1971
Country
United Kingdom
United States
Employees
493
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Real Estate Investment Trusts
Sector
Health Care
Real Estate
Exchange
Nasdaq
Nasdaq
Market Cap
1.8B
1.9B
IPO Year
2021
2006

Fundamental Metrics

Financial Performance
Metric
IMCR
DEI
Price
$36.13
$11.20
Analyst Decision
Buy
Hold
Analyst Count
9
8
Target Price
$67.00
$15.29
AVG Volume (30 Days)
259.5K
1.8M
Earning Date
11-06-2025
02-03-2026
Dividend Yield
N/A
6.79%
EPS Growth
N/A
N/A
EPS
N/A
0.12
Revenue
$379,590,000.00
$1,000,336,000.00
Revenue This Year
$32.28
$2.82
Revenue Next Year
$10.66
$1.67
P/E Ratio
N/A
$89.93
Revenue Growth
28.11
3.61
52 Week Low
$23.15
$10.92
52 Week High
$40.72
$19.13

Technical Indicators

Market Signals
Indicator
IMCR
DEI
Relative Strength Index (RSI) 48.05 32.85
Support Level $35.41 $10.92
Resistance Level $37.25 $11.22
Average True Range (ATR) 1.58 0.26
MACD -0.18 -0.01
Stochastic Oscillator 20.63 18.15

Price Performance

Historical Comparison
IMCR
DEI

About IMCR Immunocore Holdings plc

Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.

About DEI Douglas Emmett Inc.

Douglas Emmett Inc is an integrated, self-administered, and self-managed REIT. It is an owner and operator of office and multifamily properties located in coastal submarkets in Los Angeles and Honolulu. The group focuses on owning, acquiring, developing, and managing a substantial market share of office properties and multifamily communities in neighborhoods with supply constraints, high-end executive housing, and key lifestyle amenities. Its properties are located in the Beverly Hills, Brentwood, Burbank, Century City, Olympic Corridor, Santa Monica, Sherman Oaks/Encino, Warner Center/Woodland Hills and Westwood submarkets of Los Angeles County, California, and in Honolulu, Hawaii. It has two business segments, the office segment and the multifamily segment.

Share on Social Networks: